Allergan PLC is coming to grips with imminent generic competition for Restasis in the US. As the loss of exclusivity looms for its second-biggest seller, the company is counting on continued growth for top-seller Botox in both therapeutic and aesthetic indications, an expected label addition for Vraylar in bipolar depression and the potential of several other late-stage pipeline assets.
The Dublin-headquartered firm took a hit in 2018, as fourth quarter net sales income decreased 5.7% to $4.1bn and full-year...








